Anthony Carella

3.2k total citations
44 papers, 1.7k citations indexed

About

Anthony Carella is a scholar working on Virology, Infectious Diseases and Physiology. According to data from OpenAlex, Anthony Carella has authored 44 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Virology, 11 papers in Infectious Diseases and 8 papers in Physiology. Recurrent topics in Anthony Carella's work include HIV Research and Treatment (13 papers), HIV/AIDS drug development and treatment (10 papers) and Nitric Oxide and Endothelin Effects (6 papers). Anthony Carella is often cited by papers focused on HIV Research and Treatment (13 papers), HIV/AIDS drug development and treatment (10 papers) and Nitric Oxide and Endothelin Effects (6 papers). Anthony Carella collaborates with scholars based in United States and Switzerland. Anthony Carella's co-authors include Burton M. Altura, B. T. Altura, Bella T. Altura, Ray R. Arthur, Jens Bukh, David L. Thomas, Stuart C. Ray, Asefa Gebrewold, T Murakawa and Akira Nishio and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and SHILAP Revista de lepidopterología.

In The Last Decade

Anthony Carella

44 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anthony Carella United States 19 528 489 292 268 242 44 1.7k
J Giboudeau France 28 735 1.4× 610 1.2× 468 1.6× 434 1.6× 69 0.3× 104 2.5k
Olga N. Ivanova Russia 13 333 0.6× 203 0.4× 380 1.3× 63 0.2× 139 0.6× 38 973
Huan Liu China 26 205 0.4× 118 0.2× 691 2.4× 52 0.2× 200 0.8× 151 2.0k
Juha Halavaara Finland 18 1.1k 2.2× 196 0.4× 478 1.6× 57 0.2× 159 0.7× 35 2.3k
Paul W. Hruz United States 31 555 1.1× 245 0.5× 1.1k 3.7× 41 0.2× 846 3.5× 57 3.0k
L. Barbara Italy 28 863 1.6× 681 1.4× 204 0.7× 138 0.5× 46 0.2× 106 2.5k
Satoshi Kimura Japan 24 344 0.7× 101 0.2× 497 1.7× 29 0.1× 556 2.3× 104 1.9k
F. Guillot France 15 237 0.4× 101 0.2× 220 0.8× 36 0.1× 176 0.7× 28 886
Robert J. Israel United States 20 113 0.2× 46 0.1× 281 1.0× 101 0.4× 231 1.0× 89 1.6k
Hartwig Bunzendahl United States 23 632 1.2× 958 2.0× 305 1.0× 86 0.3× 185 0.8× 38 1.8k

Countries citing papers authored by Anthony Carella

Since Specialization
Citations

This map shows the geographic impact of Anthony Carella's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anthony Carella with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anthony Carella more than expected).

Fields of papers citing papers by Anthony Carella

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anthony Carella. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anthony Carella. The network helps show where Anthony Carella may publish in the future.

Co-authorship network of co-authors of Anthony Carella

This figure shows the co-authorship network connecting the top 25 collaborators of Anthony Carella. A scholar is included among the top collaborators of Anthony Carella based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anthony Carella. Anthony Carella is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
4.
Altura, Burton M., Asefa Gebrewold, Anthony Carella, et al.. (2019). Why vasculitis probably can be ameliorated with magnesium and antagonists of ceramides and platelet-activating factor. MOJ Anatomy & Physiology. 6(4). 1 indexed citations
5.
Altura, Burton M., Asefa Gebrewold, Anthony Carella, & Bella T. Altura. (2017). HDFx: A novel biologic immunomodulator may have the potential to prevent bacteria in space from becoming aggressively infectious and lethal. 3(3). 1 indexed citations
6.
Altura, Burton M., Asefa Gebrewold, Anthony Carella, & Bella T. Altura. (2016). HDFx A Novel Immunomodulator for the Amelioration of Hypovolemic Shock in the OR, Cancer Patients and on the Battlefield. 1(1). 3 indexed citations
7.
Wolkenberg, S. E., Meiqing Lu, Vandna Munshi, et al.. (2007). Novel indole-3-sulfonamides as potent HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs). Bioorganic & Medicinal Chemistry Letters. 18(2). 554–559. 76 indexed citations
8.
Lu, Zhijian, Carrie A. Rutkowski, David B. Olsen, et al.. (2005). Orally bioavailable highly potent HIV protease inhibitors against PI-resistant virus. Bioorganic & Medicinal Chemistry Letters. 15(23). 5311–5314. 8 indexed citations
9.
Shah, Shrenik K., Natalie Chen, Sander G. Mills, et al.. (2005). Synthesis and evaluation of CCR5 antagonists containing modified 4-piperidinyl-2-phenyl-1-(phenylsulfonylamino)-butane. Bioorganic & Medicinal Chemistry Letters. 15(4). 977–982. 22 indexed citations
10.
Shankaran, K., Shrenik K. Shah, Malcolm MacCoss, et al.. (2004). Syntheses and SAR studies of 4-(heteroarylpiperdin-1-yl-methyl)-pyrrolidin-1-yl-acetic acid antagonists of the human CCR5 chemokine receptor. Bioorganic & Medicinal Chemistry Letters. 14(13). 3419–3424. 14 indexed citations
11.
Shen, Dong‐Ming, Min Shu, Sander G. Mills, et al.. (2004). Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 1: Discovery and SAR study of 4-pyrazolylpiperidine side chains. Bioorganic & Medicinal Chemistry Letters. 14(4). 935–939. 22 indexed citations
12.
Zhang, Zhiqiang, William A. Schleif, Danilo R. Casimiro, et al.. (2004). The impact of early immune destruction on the kinetics of postacute viral replication in rhesus monkey infected with the simian-human immunodeficiency virus 89.6P. Virology. 320(1). 75–84. 9 indexed citations
13.
Lu, Zhijian, Subharekha Raghavan, Mark G. Charest, et al.. (2003). Design and synthesis of highly potent HIV protease inhibitors with activity against resistant virus. Bioorganic & Medicinal Chemistry Letters. 13(10). 1821–1824. 12 indexed citations
14.
Hale, Jeffrey J., Richard J. Budhu, Sander G. Mills, et al.. (2002). 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 3: polar functionality and its effect on anti-HIV-1 activity. Bioorganic & Medicinal Chemistry Letters. 12(20). 2997–3000. 10 indexed citations
16.
Willoughby, Christopher A., Scott C. Berk, Kevin T. Chapman, et al.. (2001). Combinatorial synthesis of CCR5 antagonists. Bioorganic & Medicinal Chemistry Letters. 11(24). 3137–3141. 28 indexed citations
17.
Thomas, David L., Jonathan M. Zenilman, Harrison Alter, et al.. (1995). Sexual Transmission of Hepatitis C Virus among Patients Attending Sexually Transmitted Diseases Clinics in Baltimore--An Analysis of 309 Sex Partnerships. The Journal of Infectious Diseases. 171(4). 768–775. 196 indexed citations
18.
Zhang, Aimin, Anthony Carella, Bella T. Altura, & Burton M. Altura. (1991). Interactions of magnesium and chloride ions on tone and contractility of vascular muscle. European Journal of Pharmacology. 203(2). 223–235. 6 indexed citations
19.
Altura, Burton M., et al.. (1982). Alcohol produces spasms of human umbilical blood vessels: Relationship to fetal alcohol syndrome (FAS). European Journal of Pharmacology. 86(2). 311–312. 68 indexed citations
20.
Altura, Burton M., Anthony Carella, & Bella T. Altura. (1980). Adverse effects of tris, hepes and mops buffers on contractile responses of arterial and venous smooth muscle induced by prostaglandins. Prostaglandins and Medicine. 5(2). 123–130. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026